Table 7. List of anti-cancer agents benefitted by SNEDDs .

Drug	Lipid Components	Interpretation	Ref.
Etoposide	Oleoylmacrogol-6-glycerides, Gelucire 44/14, Peceol, Transcutol** P, Plurol Oleique and Labrasol*	The formulation showed better transportation of etoposide across the Caco-2 cell lines and higher cytotoxicity than the Etosid® and free drug against A549 human epithelial lung carcinoma cell lines	176
Docetaxel	Capryol 90, Labrasol*, and Transcutol HP**	17% higher oral bioavailability for D-SNEDDs as compared to 2.6 % for Docetaxel solution, with high anti-tumor efficacy and reduced toxicity.	177
Tamoxifen citrate	Maisine 35-1, Capryol 90, Cremophor RH40*, propylene glycol**	Higher drug release from SNEDDs as compared to Tamoxifen citrate suspension.	178
Docetaxel	Maisine 35-1and Capmul MCM with Tween 80* and Transcutol-HP**	Self Nano Emulsifying Lipidic Nano-micelles System (SNELS) Formulation enriched with PUFA (Long Chain Glyceride) exhibited better dissolution, enhanced p-gp inhibition and reduced pre-systemic metabolism as depicted from in vivo pharmacokinetic studies, better permeability and absorption was also reflected from ex-vivo permeation andin situ perfusion studies. Moreover LCG based formulation were highly targeted to lymphatic system as compared to MCG (medium-chain fatty acid glyceride)	179

*Emulsifier, **Co-emulsifier.